| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $529,993 | 6 | 100 |
Sells | $0 | 0 | 0 |
| GARRETT SCOTT T | director | 2 | $269,998 | 0 | $0 | $269,998 |
| Wong Hing C | Chief Executive Officer | 2 | $219,998 | 0 | $0 | $219,998 |
| Byam Rebecca | Chief Financial Officer | 1 | $20,000 | 0 | $0 | $20,000 |
| Flowers Lee | SVP of Business Development | 1 | $19,998 | 0 | $0 | $19,998 |
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, …
Over the last 12 months, insiders at HCW Biologics Inc. have bought $529,993 and sold $0 worth of HCW Biologics Inc. stock.
On average, over the past 5 years, insiders at HCW Biologics Inc. have bought $1.1M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: GARRETT SCOTT T (director) — $269,998. Wong Hing C (Chief Executive Officer) — $219,998. Byam Rebecca (Chief Financial Officer) — $20,000.
The last purchase of 23,210 shares for transaction amount of $59,998 was made by Wong Hing C (Chief Executive Officer) on 2026‑07‑29.
| 2026-07-29 | Wong Hing C | Chief Executive Officer | 23,210 6.6894% | $2.58 | $59,998 | -22.48% | ||
| 2026-07-29 | GARRETT SCOTT T | director | 7,736 2.2296% | $2.58 | $19,998 | -22.48% | ||
| 2026-07-29 | Flowers Lee | SVP of Business Development | 7,736 2.2296% | $2.58 | $19,998 | -22.48% | ||
| 2026-05-22 | Wong Hing C | Chief Executive Officer | 113,879 2.6542% | $1.41 | $160,000 | -83.10% | ||
| 2026-05-22 | GARRETT SCOTT T | director | 177,936 4.1472% | $1.41 | $250,000 | -83.10% | ||
| 2026-05-22 | Byam Rebecca | Chief Financial Officer | 14,235 0.3318% | $1.41 | $20,000 | -83.10% | ||
| 2025-05-16 | Wong Hing C | Chief Executive Officer | 8,054 0.4658% | $7.45 | $60,002 | -69.66% | ||
| 2025-05-16 | GARRETT SCOTT T | director | 13,423 0.7763% | $7.45 | $100,001 | -69.66% | ||
| 2025-05-16 | Winer Gary M | director | 1,342 0.0776% | $7.45 | $9,998 | -69.66% | ||
| 2025-05-08 | Wong Hing C | Chief Executive Officer | 92,500 29.9424% | $26.00 | $2.4M | -53.71% | ||
| 2025-05-08 | Byam Rebecca | Chief Financial Officer | 8,462 2.7392% | $26.00 | $220,012 | -53.71% | ||
| 2025-05-08 | GARRETT SCOTT T | director | 5,385 1.7431% | $26.00 | $140,010 | -53.71% | ||
| 2025-05-08 | Flowers Lee | SVP of Business Development | 962 0.3114% | $26.00 | $25,012 | -53.71% | ||
| 2025-05-08 | Winer Gary M | director | 2,308 0.7471% | $26.00 | $60,008 | -53.71% | ||
| 2025-05-08 | Greene Rick S. | director | 962 0.3114% | $26.00 | $25,012 | -53.71% | ||
| 2023-09-14 | Wong Hing C | Chief Executive Officer | 1,800 0.0049% | $2.08 | $3,741 | -46.48% | ||
| 2023-09-14 | Winer Gary M | director | 1,041 0.0028% | $2.05 | $2,139 | -46.48% | ||
| 2023-09-13 | Byam Rebecca | Chief Financial Officer | 5,000 0.0144% | $2.10 | $10,490 | -43.32% | ||
| 2023-09-13 | Winer Gary M | director | 546 0.0015% | $2.05 | $1,117 | -43.32% | ||
| 2023-09-12 | Byam Rebecca | Chief Financial Officer | 5,000 0.0143% | $2.09 | $10,442 | -43.35% |
| Wong Hing C | Chief Executive Officer | 125845 36.1997% | $144,721.75 | 18 | 0 | <0.0001% |
| Byam Rebecca | Chief Financial Officer | 57245 16.4667% | $65,831.75 | 24 | 0 | <0.0001% |
| GARRETT SCOTT T | director | 41644 11.979% | $47,890.60 | 5 | 0 | <0.0001% |
| Flowers Lee | SVP of Business Development | 8691 2.5% | $9,994.65 | 7 | 0 | <0.0001% |
| Rhode Peter | See Remarks | 46785 13.4579% | $53,802.75 | 1 | 0 | <0.0001% |
| Jiao Jin-an | VP of Development | 30571 8.7938% | $35,156.65 | 1 | 0 | |
| Winer Gary M | director | 4075 1.1722% | $4,686.25 | 13 | 0 | <0.0001% |
| Greene Rick S. | director | 2066 0.5943% | $2,375.90 | 3 | 0 | <0.0001% |
$6,974,678 | 45 | -14.98% | $4.63M | |
$633,070 | 27 | -5.89% | $2.04M | |
HCW Biologics Inc. (HCWB) | $8,249,886 | 17 | -47.87% | $399,787.00 |
$117,515 | 16 | -27.38% | $1.66M | |
$439,090 | 12 | 8.72% | $486,870.00 |
| Increased Positions | 8 | +72.73% | 362,627 | +293.69% |
| Decreased Positions | 4 | -36.36% | 49,166 | -39.82% |
| New Positions | 5 | New | 356,648 | New |
| Sold Out Positions | <1 | Sold Out | <1 | Sold Out |
| Total Postitions | 15 | +36.36% | 436,934 | +253.87% |
| Drw Securities, Llc | $93.00 | 2.78% | 83,436 | +83,436 | New | 2025-09-30 |
| Vanguard Group Inc | $17.00 | 0.51% | 15,426 | +15,426 | New | 2025-09-30 |
| Geode Capital Management, Llc | $12.00 | 0.37% | 11,001 | +11,001 | New | 2025-09-30 |
| Golden State Wealth Management, Llc | $11.00 | 0.33% | 10,000 | 0 | 0% | 2025-09-30 |
| Wells Fargo & Company/Mn | $2.00 | 0.06% | 1,700 | 0 | 0% | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $2.00 | 0.05% | 1,562 | +1,312 | +524.8% | 2025-09-30 |
| Citigroup Inc | $0 | 0.01% | 311 | +311 | New | 2025-09-30 |
| Osaic Holdings, Inc. | $0 | <0.01% | 26 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $0 | 0% | 10 | 0 | 0% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | 0% | 1 | -5 | -83.33% | 2025-09-30 |